¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia 2022 (¿Â,¿ÀÇÁ¶óÀÎ)(1ÀÏÂ÷) : 2022-04-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia 2022 (¿Â,¿ÀÇÁ¶óÀÎ)(1ÀÏÂ÷) : 2022-04-15
±³À°ÀÏÀÚ : 2022-04-15
±³À°Àå¼Ò : °æÁÖ HICO  
±³À°ÁÖÁ¦ : 2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia 2022 (¿Â,¿ÀÇÁ¶óÀÎ)(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 80,000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ: 40,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-15 Rm.300C 08:40~08:50 Case: COVID and Myocarditis  In Cheol Kim(Keimyung Univ. Korea) 
±³À°½Ã°£ 04-15 Rm.300C 08:50~09:00 Case: Inflammatory Disease Affecting the Heart  Leslie Cooper(Mayo Clinic USA) 
±³À°½Ã°£ 04-15 Rm.300C 09:00~09:10 Case: Cancer Treatment and Myocarditis  Ana Barac(MedStar Heart and Vascular Institute USA) 
Åä·Ð 04-15 Rm.300C 09:10~09:25 Discussion  () 
È޽Ġ04-15  09:25~09:35 Break  () 
±³À°½Ã°£ 04-15 Rm.103 09:35~09:45 Nondevice Therapies and SCD Prevention  Jong-Il Choi(Korea Univ. Korea) 
±³À°½Ã°£ 04-15 Rm.103 09:45~09:55 ICDs in NICM: Who and When  Fred Kusumoto(Mayo Clinic USA) 
±³À°½Ã°£ 04-15 Rm.103 09:55~10:05 ICDs in Channelopathies and HCM  Matthew Martinez(NYU Langone Health USA) 
Åä·Ð 04-15 Rm.103 10:05~10:20 Discussion  () 
È޽Ġ04-15  10:20~10:30 Break  () 
±³À°½Ã°£ 04-15 Rm.203 10:30~10:45 Optimal Management and Monitoring during ECMO in Ptients with Cardiogenic Shock  Á¤Àç½Â(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.203 10:45~11:00 Optimal ECMO Weaning and Post-ECMO Care in Patients with Cardiogenic Shock  ¾çÁ¤ÈÆ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 04-15 Rm.203 11:00~11:15 Discussion  () 
È޽Ġ04-15  11:15~11:25 Break  () 
±³À°½Ã°£ 04-15 Rm.205 11:25~11:37 Arterial Switch Operation  °ûÀç°Ç(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.205 11:37~11:49 Ross Procedure  ¹Úõ¼ö(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.205 11:49~12:01 Fontan Operation  ¾çÁöÇõ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 04-15 Rm.205 12:01~12:10 Discussion  () 
È޽Ġ04-15  12:10~12:20 Break  () 
±³À°½Ã°£ 04-15 Rm.102 12:20~12:40 Early Bird of High Intensity Statin to close the gap betwwen theory and practice in ACS patients  ¹æ´ö¿ø(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.102 12:40~13:00 When and why combination therapy is needed for dyslipidemia patients? as the next option of maximum tolerable mono statin therapy.  ¼ÕÁ¤¿ì(¿¬¼¼¿øÁÖÀÇ´ë) 
È޽Ġ04-15  13:00~13:10 Break  () 
±³À°½Ã°£ 04-15 Rm.102 13:10~13:30 Expanding Role of Entresto for HF with below normal EF  Gregg C. Fonarow(Ronald Reagan UCLA Medical Center USA) 
±³À°½Ã°£ 04-15 Rm.102 13:30~13:50 Evolving role of Entresto as first choice for your HF patient  Hyun-Jai Cho(Seoul National Univ. Korea) 
È޽Ġ04-15  13:50~14:00 Break  () 
±³À°½Ã°£ 04-15 Rm.105 14:00~14:12 How to decide rhythm or rate control strategy  ¹ÚÁ¾¼º(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.105 14:12~14:24 Current results of radiofrequency or Cryo ablation for AF  °íÁ¡¼®(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.105 14:24~14:36 New technologies for AF detection and management  À¯ÈñÅÂ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 04-15 Rm.105 14:36~14:45 Discussion  () 
È޽Ġ04-15  14:45~14:55 Break  () 
±³À°½Ã°£ 04-15 Rm.105 14:55~15:07 How to Find Culprit Lesion and Manage Non-Culprit Lesion: Imaging and Physiology  ±èÇö±¹(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.105 15:07~15:19 How to Overcome Coronary Thrombosis During Primary PCI  À±¿µÁø(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.105 15:19~15:31 Which Is the First Strategy in AMI with Cardiogenic Shock: VA-ECMO or PCI?  Àå¿ìÁø(ÀÌÈ­ÀÇ´ë) 
Åä·Ð 04-15 Rm.105 15:31~15:40 Discussion  () 
È޽Ġ04-15  15:40~15:50 Break  () 
±³À°½Ã°£ 04-15 Rm.205 15:50~16:10 Murine and Rodent Model  À̽ÂÁØ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.205 16:10~16:30 Pig Model  ÀÓ°æ¼·(Çѱ¹»ý¸í°øÇבּ¸¿ø) 
±³À°½Ã°£ 04-15 Rm.205 16:30~16:50 In Vitro Model: Cell Line and Patient Specific iPSC-derived Cardiovascular Cell  ¾çÇѸð(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-15 Rm.205 16:50~17:10 Electrophysiology and Echocardiography Evaluation in Animal Model  °íÅÂÈñ(°í·ÁÀÇ´ë) 
Åä·Ð 04-15 Rm.205 17:10~17:20 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia 2022 (¿Â,¿ÀÇÁ¶óÀÎ)(1ÀÏÂ÷) : 2022-04-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Çѱ¹¿©ÀÚÀÇ»çȸ COVID-19ÀÇ ÀÌÇØ : 2022-04-15
´ÙÀ½±Û 2022³â ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è Çмú´ëȸ(2ÀÏÂ÷) : 2022-04-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20559 °æ±â Á¦34Â÷ Áß¾Ó´ëÇб³ ºñ´¢ÀÇÇаú ¿öÅ©¼¥ : 2024-06-01 0 50 2024-04-29
20558 ±¤ÁÖ Á¦2ȸ ´ëÇѺñ¸¸ÇÐȸ È£³²Áöȸ Çмú´ëȸ : 2024-06-01 0 56 2024-04-29
20557 ÀÎõ 2024³â ±èÆ÷½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-01 0 36 2024-04-29
20556 ¼­¿ï 2024 ´ëÇÑ¿ì¿ïÇൿ½Å°æÇבּ¸È¸ Ãá°èÇмú´ëȸ : 2024-06-01 0 39 2024-04-29
20555 ¼­¿ï ´ëÇѽÉÀåÇ÷°üÈäºÎ¿Ü°úÇÐȸ Á¦38Â÷ Ãá°èÅëÇÕÇмú´ëȸ ¹× ¿¬¼ö±³À° (2ÀÏÂ÷) : 2024-06-01 0 27 2024-04-29
20554 ¼­¿ï Á¦ 14Â÷ ´ëÇѸð¹ßÀ̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-01 0 31 2024-04-29
20553 ¼­¿ï 2024³â ´ëÇѼҾư¨¿°ÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-31 0 45 2024-04-29
20552 Àü³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ - Á¦297Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-31 0 64 2024-04-29
20551 ¼­¿ï (¿Â¶óÀÎ) 2024 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-31 0 78 2024-04-29
20550 ºÎ»ê Á¦ 169Â÷ ºÎ»êÁö¹æ³²¼º°úÇÐȸ Çмú´ëȸ : 2024-05-31 0 43 2024-04-29
20549 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦26ȸ ¿¬¼ö°­Á : 2024-05-30 0 38 2024-04-29
20548 °­¿ø 2024³â ¿øÁÖ½ÃÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß : 2024-05-28 0 47 2024-04-29
20547 °æ±â Á¦4ȸ ´ëÇÑ¿Ü°úÇÐȸ ¿Ü°ú³»½Ã°æ ¿¬¼ö°­Á : 2024-05-26 0 54 2024-04-29
20546 ¼­¿ï ´ëÇѺñ´¢ÃÊÀ½ÆÄÇÐȸ Á¦17Â÷ Çмú´ëȸ : 2024-05-26 0 33 2024-04-29
20545 °æºÏ 2024³âµµ °æ»óºÏµµÀÇ»çȸ Á¾ÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-26 0 60 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷